Tags

Type your tag names separated by a space and hit enter

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet. 2005 Apr 16-22; 365(9468):1389-97.Lct

Abstract

BACKGROUND

In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.

METHODS

patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the intention-to-treat population.

FINDINGS

Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3.4 kg [SD 5.7]; p=0.002 vs placebo) and 20 mg (-6.6 kg [7.2]; p<0.001 vs placebo) compared with placebo (-1.8 kg [6.4]). Significantly more patients treated with rimonabant 20 mg than placebo achieved weight loss of 5% or greater (p<0.001) and 10% or greater (p<0.001). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome. The effects of rimonabant 5 mg were of less clinical significance. Rimonabant was generally well tolerated with mild and transient side effects.

INTERPRETATION

CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.

Authors+Show Affiliations

Department of Diabetology, Metabolism, and Clinical Nutrition, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem-Antwerp, Belgium. luc.van.gall@uza.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15836887

Citation

Van Gaal, Luc F., et al. "Effects of the Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-year Experience From the RIO-Europe Study." Lancet (London, England), vol. 365, no. 9468, 2005, pp. 1389-97.
Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389-97.
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (London, England), 365(9468), 1389-97.
Van Gaal LF, et al. Effects of the Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-year Experience From the RIO-Europe Study. Lancet. 2005 Apr 16-22;365(9468):1389-97. PubMed PMID: 15836887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. AU - Van Gaal,Luc F, AU - Rissanen,Aila M, AU - Scheen,André J, AU - Ziegler,Olivier, AU - Rössner,Stephan, AU - ,, PY - 2005/4/20/pubmed PY - 2005/5/4/medline PY - 2005/4/20/entrez SP - 1389 EP - 97 JF - Lancet (London, England) JO - Lancet VL - 365 IS - 9468 N2 - BACKGROUND: In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients. METHODS: patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the intention-to-treat population. FINDINGS: Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3.4 kg [SD 5.7]; p=0.002 vs placebo) and 20 mg (-6.6 kg [7.2]; p<0.001 vs placebo) compared with placebo (-1.8 kg [6.4]). Significantly more patients treated with rimonabant 20 mg than placebo achieved weight loss of 5% or greater (p<0.001) and 10% or greater (p<0.001). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome. The effects of rimonabant 5 mg were of less clinical significance. Rimonabant was generally well tolerated with mild and transient side effects. INTERPRETATION: CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors. SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/15836887/Effects_of_the_cannabinoid_1_receptor_blocker_rimonabant_on_weight_reduction_and_cardiovascular_risk_factors_in_overweight_patients:_1_year_experience_from_the_RIO_Europe_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)66374-X DB - PRIME DP - Unbound Medicine ER -